Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial Marks, D. I., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S., Jabbour, E., Merchant, A., Wang, T., Vandendries, E., Neuhof, A., Advani, A., Kantarjian, H. NATURE PUBLISHING GROUP. 2019: 149–51
View details for Web of Science ID 000487707800154